Early Temozolomide in Patients With High-Grade Gliomas in Rehabilitation
| Status: | Not yet recruiting |
|---|---|
| Conditions: | Brain Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 1/10/2019 |
| Start Date: | February 1, 2019 |
| End Date: | February 1, 2020 |
| Contact: | Kwanza Warren |
| Email: | kwanza_warren@urmc.rochester.edu |
| Phone: | 585-276-3581 |
Early Post-surgical Temozolomide Therapy in Patients With High-Grade Gliomas Admitted to Acute Rehabilitation: A Feasibility Study
The purpose of this study is to investigate the feasibility of a possible treatment regimen
that could be used to delay tumor progression in patients with glioblastoma. The study is
being conducted in patients who qualify for inpatient rehabilitation, as this population is
particularly vulnerable to delays in initiation of chemoradiation and further tumor growth in
the period between surgical resection and the start of treatment.
that could be used to delay tumor progression in patients with glioblastoma. The study is
being conducted in patients who qualify for inpatient rehabilitation, as this population is
particularly vulnerable to delays in initiation of chemoradiation and further tumor growth in
the period between surgical resection and the start of treatment.
This is a pilot study to evaluate the feasibility and safety of early postsurgical
temozolomide therapy prior to initiation of standard chemoradiation regimen in patients with
glioblastoma who undergo inpatient rehabilitation. The study will be conducted with adult
patients who qualify for inpatient rehabilitation following surgical resection of
pathologically confirmed Grade IV glioma. Patients will receive a single 5-day cycle of
temozolomide starting 14 days after surgery at 75mg per square meter of body surface area
daily to serve as bridge therapy. Patients will then progress to receive standard therapy
following their rehabilitation stay. Patients will be assessed for their ability to complete
the chemotherapy protocol without dose-limiting toxicity as well as complete inpatient
rehabilitation successfully. Additionally, we will be assessing for tumor progression between
the time of surgery and the time of treatment initiation.
If this study shows the expected results, the research team plans to proceed to a larger
trial assessing the efficacy of early TMZ in patients with glioblastoma (GBM) who are
admitted to acute inpatient rehabilitation compared to the current standard of care.
temozolomide therapy prior to initiation of standard chemoradiation regimen in patients with
glioblastoma who undergo inpatient rehabilitation. The study will be conducted with adult
patients who qualify for inpatient rehabilitation following surgical resection of
pathologically confirmed Grade IV glioma. Patients will receive a single 5-day cycle of
temozolomide starting 14 days after surgery at 75mg per square meter of body surface area
daily to serve as bridge therapy. Patients will then progress to receive standard therapy
following their rehabilitation stay. Patients will be assessed for their ability to complete
the chemotherapy protocol without dose-limiting toxicity as well as complete inpatient
rehabilitation successfully. Additionally, we will be assessing for tumor progression between
the time of surgery and the time of treatment initiation.
If this study shows the expected results, the research team plans to proceed to a larger
trial assessing the efficacy of early TMZ in patients with glioblastoma (GBM) who are
admitted to acute inpatient rehabilitation compared to the current standard of care.
Inclusion Criteria:
- Adult patients, aged 18+
- Newly diagnosed World Health Organization (WHO) Grade IV glioma, confirmed on
pathology
- Karnofsky Performance Score ≥ 60
- Subject has undergone biopsy, subtotal resection, or gross total resection of tumor
- Subject has been evaluated by physical therapy and thought to be a candidate for acute
rehabilitation
- Subject must be accepted for admission on 5-1200 unit at Strong Memorial Hospital
- Subject must be able to provide informed consent
- Subject must meet the following laboratory parameters:
- Absolute neutrophil count > 1.5 x103/uL
- Platelet count > 140 x103/uL
- Alanine transaminase < 135 U/L
- Aspartate transaminase < 120 U/L
Exclusion Criteria:
- Subject has received previous treatment for high-grade glioma
- Subject has other active malignancy
- Subject is currently pregnant or breastfeeding
- Subject is a women of childbearing potential who is not using a reliable method of
contraception
- Subject has history of hypersensitivity to temozolomide
We found this trial at
1
site
601 Elmwood Avenue
Rochester, New York 14642
Rochester, New York 14642
(585) 275-2100
Phone: 585-276-3581
Univ of Rochester Medical Center One of the nation's top academic medical centers, the University...
Click here to add this to my saved trials
